Hemant Vishwakarma THESEOBACKLINK.COM hello@theseobacklink.com
Welcome to THESEOBACKLINK.COM
Email Us - hello@theseobacklink.com
directory-link.com | webdirectorylink.com | smartseobacklink.com | directoryweb.link

Links -> Link Details

Title Bristols’ DLBCL CAR-T Therapy -Lisocabtagene Maraleucel (JCAR017)- Mellalta Meets Findings
URL https://mellalta.com/bristols-dlbcl-car-t-therapy-lisocabtagene-maraleucel-jcar017-future-strategy-latest-events/
Category Fitness Health --> Disabilities and Disorders
Meta Keywords liso-cel and JCAR017, Lisocabtagene maraleucel , CAART, CART therapy, CAAR T Cell, Autoimmune Disease, Bristol, EMA, Juno Therapeutics, Bristol
Meta Description On July 17, 2020, Bristol’s liso-cel was validated for MAA by EMA for Relapsed or refractory (R/R) diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B. The Therapy is also under review by FDA
Owner Emma Stones
Description
Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge. The therapy is a key pipeline asset which Bristol-Myers picked up through its takeover of Celgene, originally belongs to Juno Therapeutics.